The characteristic t(15;17) of acute promyelocytic leukemia (APL) fuses the retinoic acid receptor a
reported breakpoint. DNA sequencing of the predominant RT-PCR products from 6 patients showed identical RAR-a exonic breakpoints and two PML breakpoints. This RT-PCR assay was positive in leukemic cells from 30/30 APL patients with the molecular rearrangement confirmed by cytogenetics or Northern analysis. In leukemic cells of patients with a morphologic diagnosis of APL lacking the t(15;17) by routine cytogenetics, a positive RT-PCR assay predicted clinical response to all-trans-retinoic acid (RA) therapy. Dilutional studies with leukemic cells that express (NB4) or do not express (HL-60) a PML/RAR-a fusion mRNA reveal that this RT-PCR assay detects the transcript from as little as 50 pg of total RNA. In APL cells from 5/6 patients treated with RA alone, a complete response by clinical and cytogenetic criteria accompanied a persistently positive RT-PCR assay. This preceded relapse by 1-6 months. RT-PCR for PML/RAR-a mRNA provides a more-sensitive test for the t(15;17) than routine cytogenetics or Northern analysis. This molecular rearrangement detected by RT-PCR best defines this RA-responsive malinancy. The RT-PCR assay for the PML/RAR-a transcript yields important diagnostic and prognostic information in the management of APL patients.
Acute promyelocytic leukemia (APL) is a distinct clinical and histopathologic subtype of acute myeloblastic leukemia. APL is associated with a unique cytogenetic abnormality, t(15;17)(q22;ql2-21) (1). Recognition of this subtype of leukemia is important because of its potential for life-threatening disseminated intravascular coagulation (2) and the dramatic clinical response to all-trans-retinoic acid (RA) treatment limited to this form of leukemia (3) (4) (5) .
The characteristic t(15;17) ofAPL creates a fusion between a newly described gene (PML) on chromosome 15 and the RA nuclear receptor a (RAR-a) (6) (7) (8) . The fusion gene is expressed at the mRNA level in leukemic cells isolated from APL patients (5, (9) (10) (11) . The cDNA clones from several APL cellular samples have been isolated and sequenced, revealing at least two different exonic fusion sequences (7, 8, 12) . The breakpQint in the RAR-a gene ofAPL cells is found uniformly between the first and second coding exons. Two fragments of the PML gene, differing in their 3' region, contribute to the rearranged PML/RAR-a cDNA (7, 8, 12) . These molecular findings have been used to examine leukemic cells of patients for the presence of the PML/ RAR-a rearrangement. Northern analysis can detect abnormal RAR-a in most clinical APL cases if a sufficient quantity of intact RNA is obtained from the leukemic cells (5, (9) (10) (11) . When adequate genomic DNA is obtained, Southern analysis with exonic probes detects a fraction ofAPL cases (5, 10, 11) . The use of multiple intronic probes for both RAR-a and PML allows detection of most, if not all, rearrangements (13, 14) . Reverse transcription polymerase chain reaction (RT-PCR) with primers derived from the cloned PML/RAR-a sequences has amplified the fusion molecule in selected cases (7, 8, 12 (15) . This technique provides a high yield of intact RNA from these RNase-enriched cells (5, 9) . Northern analysis was performed with transfer to reinforced nitrocellulose filters by standard techniques (16) . The obtained filters were hybridized to [a-32P]dCTP radiolabeled DNA probes and washed as described (9) . Autoradiography was with Kodak XAR film and exposure to an intensifying screen at -70°C. The RAR-a probes were either a 600-basepair (bp) Pst I or a 640-bp EcoRI/Sst I-cut insert purified from a plasmid containing the full-length RAR-a cDNA (17, 18 This was radiolabeled with [a-32P]dCTP using commercial random-priming kits.
RT-PCR Assay for PML/RAR-a Expression. Patients diagnosed with APL (M3) by morphologic criteria (19) were entered into a clinical trial investigating RA as single-agent therapy. Patients or their guardians gave written informed consent, and the study was reviewed and approved in advance by the center's institutional review board. Karyotypes were determined on unstimulated bone marrow cultures after 48 hr with the use of Giemsa-or quinacrine-banding techniques (20) . Leukemic cells from APL patients were examined for the presence of the PML/RAR-a fusion mRNA. Total RNA from bone marrow aspirates was subjected to RT with random hexamers and Moloney murine leukemia virus reverse transcriptase followed by 40-50 cycles of PCR amplification (GeneAmp 9600, Perkin-Elmer/Cetus) (21) . Maximum sensitivity was obtained without nonspecific amplification using 50 cycles (data not shown). Primers for RAR-a were synthetic 20-nucleotide oligomers at bases 235 (5' primer) and 404 (3' primer) of the cloned RAR-a cDNA (18) . Primer pair II for PML/RAR-a comprised a 5' 20-nucleotide oligomer from the cloned PML cDNA (base 1074) (7) and the 3' 20-nucleotide primer from RAR-a (base 404) (18) . Primer pair I comprised flanking 20-mers at base 997 of PML and base 462 of RAR-a. Primer III was a 20-mer spanning bases 1482-1501 of PML (7) . PCR products were electrophoresed on 2% NuSieve/1% SeaKem agarose (FMC) gels in a Tris borate/Na2-EDTA buffer and visualized by staining with ethidium bromide. The specificity of PCR amplification was also examined by Southern blotting the amplified cDNA with hybridization to 32P-labeled probes for a 1000-bp EcoRI/Kpn I fragment of the PML cDNA or the 640-bp EcoRI/Sst I fragment of the RAR-a cDNA (7, 18) . A control for the integrity of RNA isolated from the bone marrow mononuclear cells was the simultaneous RT-PCR amplification of the RAR-a mRNA.
PCR amplification by the nested primer technique was performed by using primer pair II for 25 cycles followed by primer pair I for 25 cycles as described (22) . To evaluate the sensitivity of this assay in leukemic cells, NB4 cells expressing the PML/RAR-a transcript (ref. 23 Fig. 1C (lanes 3 and 4) . RT (7, 8) . Nucleic acid sequence contributed by RAR-a is underlined. (C) Application of the RT-PCR assay for the PML/RAR-a fusion mRNA to bone marrow mononuclear cells isolated from APL patients. The RT-generated cDNA from APL bone marrow samples or from control cells was amplified by using primer pair II (lanes 1-6) or primer pair I (lanes 7-12). The RT-PCR products were electrophoresed as described and were visualized by staining with ethidium bromide. Lanes: 1 and 2, two APL cases expressing pattern A; 3 and 4, two APL cases expressing pattern B; 5 and 6, non-APL controls. In lanes 7-12, the cDNA used in lanes 1-6 was amplified with an internal primer pair. Molecular size standards (bp) appear on the left. To evaluate the specificity of the multiple bands in Fig. 1C , PCR amplification was performed with primer pair I, which hybridizes internal to the sequence amplified by primer pair II (see Fig. 1B ). As shown in Fig. 1C the PCR amplified bands in lanes 7-10 are similar to those in lanes 1-4 except that each species is decreased in size by 131 bp. To confirm that these ethidium bromide-stained bands were specific RT-PCR amplification products of the PML/RAR-a transcript, the amplified cDNA was blotted and hybridized to PML-and RAR-a-specific probes. Southern analysis was performed on the size-fractionated RT-PCR products depicted in Fig. 1C by using appropriate radiolabeled PML or RAR-a probes. Autoradiography identified all the species visualized by ethidium bromide staining (data not shown).
Similar multiple bands were found in the RT-PCR amplified RNA from APL cells of other patients expressing pattern B. Autoradiography of Southern blot hybridizations of these RT-PCR products to PML-specific probes revealed up to six distinct bands (data not shown). This RT-PCR finding might arise from the presence of an alternative splicing site in the PML sequence included in the fusion mRNA of APL cells expressing pattern B, but not in cells expressing pattern A. RT-PCR was performed on RNA from leukemic cells of a representative patient with each expression pattern. This was accomplished with a 5' primer from the PML sequence 3' to the reported alternative splicing site (labeled III in Fig. 1B ) (7, 8) . These data suggest that the two patterns seen by Northern analysis or RT-PCR amplification correspond to the two reported breakpoints for the PML/RAR-a fusion mRNA depicted in Fig. 1B patient expressing pattern A, the PML breakpoint occurred at base 1263 (7), and the RAR-a breakpoint occurred at base 281 (18) . The leukemic cells from three patients expressing pattern B had RAR-a breakpoints identical to those ofpattern A but had all PML breakpoints at base 1737 (7). Assay Sensitivity. Dilutions of plasmid DNA containing PML/RAR-a cDNA as an insert were amplified to assess the sensitivity of PCR amplification. PCR amplification with primer pair I for 50 cycles of as little as 300 molecules of this PML/RAR-a cDNA (7) yielded a 314-bp PML/RAR-a band detectable by hybridization to a PML-specific oligonucleotide probe (data not shown). The RT-PCR assay performed on RNA isolated from leukemic bone marrow aspirates of patients expressing pattern A required only 50 pg of RNA to yield a detectable 314-bp PML/RAR-a band. Successful RT-PCR amplification of RNA isolated from leukemic bone marrow aspirates of patients expressing pattern B required 0.5-10 ng of RNA to detect the larger PML/RAR-a species. The use of a nested primer PCR amplification technique increased sensitivity for these larger PML/RAR-a species by 10-to 100-fold. Using the nested primer technique, RNA prepared from APL bone marrow mononuclear cells expressing either reported PML/RAR-a transcript is RT-PCR amplified with enhanced sensitivity. In experiments with clinical APL specimens, RT-PCR amplification of RNA for the nonrearranged RAR-a allele, which is coexpressed with the PML/RAR-a transcript, was a control for RNA integrity. Fifty picograms of cDNA prepared from intact total RNA was routinely sufficient to detect the 169-bp amplified RAR-a fragment. To explore the sensitivity of this assay to detect isolated leukemic cells, NB4 cells, which express PML/ RAR-a (23), were mixed with increasing proportions of the nontranslocated HL-60 cells. As shown in Fig. 3 , PML/ RAR-a can be detected by ethidium bromide staining of the cDNA produced from as little as 50 pg of NB4 total RNA.
Clinical Application of the RT-PCR Assay. Thirty-six patients meeting clinical criteria for the diagnosis of APL were entered into a trial investigating the antitumor activity of RA. Leukemic cells isolated from these patients were examined for expression of the PML/RAR-a fusion mRNA by RT- PCR. As shown in Table 1 Fig. 1A legend) ; NE, not evaluable (indicating total RNA yields that were insufficient for Northern analysis); -, no abnormal RAR-a mRNA (Northern), no RT-PCR amplified PML/ RAR-a (PCR), or no response to RA (RA response); ED, early death; +, clinical response to RA therapy. cytogenetic findings, identification of a PML/RAR-a fusion mRNA by the RT-PCR assay predicted the CR induced by RA in all clinically evaluable patients. Table 1 correlates the pattern seen on Northern analysis with that seen by the RT-PCR assay. Twenty-seven of 31 patients with adequate leukemic cell RNA for Northern analysis showed one of the two patterns ( Fig. 1 A and B) of aberrant RAR-a expression. These patients were all positive by RT-PCR, with the amplified cDNA pattern matching the pattern seen on Northern analysis. The leukemic cells from 4 patients exhibiting only normal RAR-a expression on Northern analysis were also negative by RT-PCR. In 5 cases, Northern analyses performed on mononuclear bone marrow cells were not evaluable because of inadequate total RNA yields or nonintact RNA. In each of these patients, the RT-PCR assay was diagnostic for the PML/RAR-a transcript, indicating the enhanced clinical sensitivity of this assay.
The RT-PCR assay was used serially in bone marrow mononuclear cells from APL patients responding to RA treatment. At the time of entry into CR defined by conventional clinical and cytogenetic criteria, the RT-PCR remained positive in the bone marrow cells from all patients evaluated. Six of these patients remained on continuous RA treatment and received no cytotoxic therapy. All of these patients relapsed within 3-10 months. The subsequent bone marrow mononuclear samples yielded RNA and cDNA of variable quality. The presence of the PML/RAR-a transcript was determined in bone marrow specimens with RNA ofadequate integrity to detect expression of the nontranslocated RAR-a species. Using the nested primer assay, PML/RAR-a was detected in all the evaluable specimens from 5/6 patients. In the patient with the most durable CR (10 (3) (4) (5) 26) . We previously found that abnormal RAR-a mRNA expression correlates with the ability of RA to induce maturation of leukemic cells and clinical remission (5, 9) . With the cloning of the PML/RAR-a fusion cDNA (7, 8, 12) , it is possible to design specific molecular probes. Genomic DNA probes have been derived to reveal DNA rearrangements in APL cells (11, 13, 14) . The more sensitive RT-PCR method identified PML/RAR-a transcripts in selected cases (7, 8) .
This study describes an RT-PCR assay that detects both reported forms of the PML/RAR-a rearrangement with high sensitivity. This (27) . The The two patterns of abnormal RAR-a expression seen on Northern analysis correspond to the two patterns of RT-PCR amplified products. In cells expressing the PML/RAR-a transcript of pattern B, multiple specific amplification products were seen. These multiple forms may result from alternative splicing in the PML portion of the fusion molecule. Consistent with this interpretation, the number of RT-PCR species decreased with the use of a more distal PML primer (primer III in Fig. 1B) .
These multiple amplified forms and the difficulty in purification of intact, high molecular weight RNA from APL cells (5) may account for the decreased sensitivity of the RT-PCR assay for RNA of pattern B. As reported in other systems (22) , sensitivity was increased by use of nested primers. With the described RT-PCR assay, PML/RAR-a of either pattern could be detected from 50-500 pg of bone marrow mononuclear cell RNA. This is somewhat higher than the 10 pg of RNA required for detection of BCR/ABL fusion RNA in CML cells (28) . Since the PCR assay for PML/RAR-a is quite sensitive for the amplification of plasmid DNA containing the PML/RAR-a cDNA, these differences in sensitivity might reflect lower levels ofPML/RAR-a expression in APL cells than of BCR/ABL in CML cells.
An important application for this sensitive and specific assay for PML/RAR-a expression is the detection of minimal residual disease. Despite the high CR rate to RA therapy, most patients relapse who are not given cytotoxic chemotherapy after an RA-induced remission (26, 29) . This RT-PCR assay detected the presence of APL leukemic cells during clinical CR in six of six patients treated with RA alone. Only one RNA sample containing amplifiable normal RAR-a mRNA (a control for RNA integrity) was negative by the nested RT-PCR assay for PML/RAR-a. This occurred in bone marrow cells from the single patient who remained in continuous CR for 10 months. Perhaps in this patient with the most durable CR after RA treatment the number of PML/ RAR-a-expressing cells fell transiently below the assay's sensitivity. The assay was positive in only three of eight patients in CR after cytotoxic chemotherapy. It is not yet clear whether RT-PCR positivity will predict relapse in this group or in those who received consolidation chemotherapy after a RA-induced remission. If this assay proves to be an accurate predictor of relapse, it may become possible to distinguish subsets of APL patients who would benefit from additional therapy. Alternatively, cured patients could be spared the risks of additional chemotherapy treatment.
In summary, this RT-PCR assay for the PML/RAR-a fusion mRNA provides an important tool for the molecular diagnosis of APL. The assay is a more sensitive and specific predictor ofclinical response to RA therapy than either light microscopy or cytogenetics. The RT-PCR assay also permits molecular dissection of the fusion transcript and correlation of its expression pattern in bone marrow cells during treatment ofAPL patients. Our initial findings show that this assay provides critical prognostic information through the detection of minimal residual disease in the bone marrow aspirates of patients in clinical CR after RA therapy. Ultimately, this assay might be useful to determine the amount and adequacy of postremission therapy administered to APL patients.
